Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 375 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fed Clear all
Completed Phase 3 Interventional

Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula

NCT01573871
View directory record Official record
Conditions
Infant, Gastrointestinal Intolerance
Interventions
Experimental Hydrolyzed infant formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 180 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Indianapolis, Indiana • Cleveland, Ohio • Huber Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

NCT02821338
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine Extended Release
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 5, 2026, 11:36 PM EDT
Recruiting No phase listed Observational

LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study

NCT06217588
View directory record Official record
Conditions
LCAT Deficiency
Interventions
Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
40 participants
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 11:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Term Infants Fed a Partially Hydrolyzed Whey Protein-Based Formula

NCT04934397
View directory record Official record
Conditions
Gastro-Intestinal Tolerance
Interventions
Study Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
7 Days to 65 Days
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Dothan, Alabama • Spring Hill, Florida • Idaho Falls, Idaho + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

NCT02184585
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02077803
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

NCT01454622
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 5, 2026, 11:36 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri

NCT01067027
View directory record Official record
Conditions
Colic
Interventions
Lactobacillus reuteri
Dietary Supplement
Lead sponsor
Children's Investigational Research Program, LLC
Other
Eligibility
14 Days to 60 Days
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bentonville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growth and Tolerance of Young Infants Fed Infant Formula

NCT04105686
View directory record Official record
Conditions
Growth and Tolerance
Interventions
Control Infant Formula, Experimental Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 14 Days
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions

NCT00775359
View directory record Official record
Conditions
Healthy
Interventions
Fenofibrate 160 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2008 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition

NCT01888328
View directory record Official record
Conditions
Healthy
Interventions
Isotretinoin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Quadrangle Drive, Chapel Hill,, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects

NCT00932880
View directory record Official record
Conditions
Healthy
Interventions
Amlodipine Besylate, Norvasc
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years to 45 Years
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Not applicable Interventional

Infants Fed a Hydrolyzed Infant Formula

NCT05369494
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Hydrolyzed protein infant formula with oligosaccharides
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
0 Days to 90 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Orange City, Florida • Fayetteville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension

NCT00853190
View directory record Official record
Conditions
Healthy
Interventions
Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

NCT01703468
View directory record Official record
Conditions
Seizures
Interventions
Oxcarbazepine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

NCT02089295
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fed Bioavailability Study of Zonisamide Capsules

NCT00687167
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide 100 mg Capsule, Zonisamide (Zonegran®) 100 mg Capsule
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage in the Fed and Fasted States

NCT05266248
View directory record Official record
Conditions
Pharmacokinetics
Interventions
250 mg encapsulated caffeine
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 5, 2026, 11:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Unintentional Overfeeding of Formula Fed Infants

NCT02701868
View directory record Official record
Conditions
Childhood Obesity, Infant Development
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Torsemide Tablets Under Fed Conditions

NCT00602615
View directory record Official record
Conditions
Edema
Interventions
Torsemide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Tolerance of Healthy Term Infants Fed Infant Formulas #4

NCT01155414
View directory record Official record
Conditions
Healthy Term Infants
Interventions
Hydrolysate based infant formula, Investigational Infant Formula A, Investigational Infant Formula B
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
1 Day to 8 Days
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
10
States / cities
Birmingham, Alabama • Dothan, Alabama • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Sep 5, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions

NCT01276080
View directory record Official record
Conditions
Healthy
Interventions
Donepezil
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Sep 5, 2026, 11:36 PM EDT